year 14, Issue 5 (September - October 2020)                   Iran J Med Microbiol 2020, 14(5): 388-407 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammad Shafiei P, Baserisalehi M, Mobasherizade S. Investigating the Antibiotic Resistance Prevalence and Phenotypic and Genotypic Evaluation of AcrAB-OprM Efflux Pump in Multidrug-resistant in Clinical Isolates of Moraxella catarrhalis in Kazerun City, Iran. Iran J Med Microbiol. 2020; 14 (5) :388-407
1- Department of Microbiology, Faculty of Science, Islamic Azad University, Kazeroun, Iran
2- Department of Microbiology, Faculty of Science, Islamic Azad University, Kazeroun, Iran ,
3- Hospital Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:   (1941 Views)
Background and Objective: Moraxella catarrhalis a gram-negative bacterium, is a significant cause of lower and upper respiratory infections. The RND family efflux pumps lead to multidrug resistance in gram-negative bacteria. One of the well-known pumps in M. catarrhalis is AcrAB-OprM system. This study aimed to investigate the antibiotic resistance in M. catarrhalis and to determine its antibiotic resistance dependence on the efflux pump.
Methods: In this study, 137 different clinical samples were collected. M. catarrhalis isolates were confirmed by biochemical assays and PCR. The antibiotic susceptibility pattern was investigated by disc diffusion method according to CLSI. Phenotypic study of the efflux pumps activity was done using cartwheel method. Study of the acra, acrb, and oprm genes were performed by, PCR. In addition, the association of efflux pump with antibiotic resistance was investigated using phenylalanine-arginine β-naphthylamide.
Results: Of 10 isolated M. catarrhalis, 70% (7 isolates) showed multiple antibiotic resistance. The resistance to cefazolin, ceftazidime, tetracycline, chloramphenicol, and ciprofloxacin antibiotics was also dependent on the efflux pump.
Conclusion: The results showed that multiple antibiotic resistance has increased in Moraxella catarrhalis. The 70% presence of acra, acrb, oprm efflux genes of the efflux pumps in this bacterium and antibiotic resistance reduction in the presence of efflux pump inhibitor shows the importance of examining these genes’ presence to suggest a suitable treatment model for the patients infected with M. catarrhalis.
Full-Text [PDF 1107 kb]   (694 Downloads) |   |   Full-Text (HTML)  (906 Views)  
Type of Study: Original | Subject: Antibiotic Resistance
Received: 2020/06/3 | Accepted: 2020/08/10 | ePublished: 2020/09/1

1. Enright MC, McKenzie H. Moraxella (Branhamella) catarrhalis. Clinical and molecular aspects of discovered pathogen. J Med Microbiol 1997; 46(5): 360-71 [DOI:10.1099/00222615-46-5-360] [PMID]
2. Tamang MD, Dey S, Makaju RK, Jha BK, Shivananda PG, Bhramadatan KN. Prevalence of Moraxella catarrhalis infections of the lower respiratory tract in elderly patients. Kathmandu Univ Med J (KUMJ). 2005;3(1):39-44
3. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis.2009;49(1): 124-131 [DOI:10.1086/599375] [PMID]
4. Wald ER. Sinusitis. Pediatr Ann 1998 Dec; 27(12):818-8 [DOI:10.3928/0090-4481-19981201-08] [PMID]
5. Spaniol V, Bernhard S ,Aebi CH. Moraxella catarrhalis AcrAB-OprM Efflux Pump Contributes to Antimicrobial Resistance and Is Enhanced during Cold Shock Response. Antimicrob Agents Chemother. 2015; 59(4): 1886-1894. [DOI:10.1128/AAC.03727-14] [PMID] [PMCID]
6. Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochemical and biophysical research communications. 2014;453(2):254-67. [DOI:10.1016/j.bbrc.2014.05.090] [PMID]
7. Webber M, Piddock L. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chem. 2003;51(1):9-11 [DOI:10.1093/jac/dkg050] [PMID]
8. Du D,Wang-kan X,Neuberger A,W.Van Veen H, M.Pos K,J. V. Piddock L et al. Multidrug efflux pumps: structure, function and regulation.NatureReviewsMicrobiology.2018;16(9):523-539 [DOI:10.1038/s41579-018-0048-6] [PMID]
9. Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta.2009;1794(5):769-781. [DOI:10.1016/j.bbapap.2008.10.004] [PMID] [PMCID]
10. Valadkhani F, Zeighami H. Efflux pump systems in bacteria. Lab Diagn. 2016; 8(33): 35-43. [In Persian]
11. Stavri M, Piddock LJ, Gibbons S.Bacterial efflux pump inhibitors from natural sources. J of antimicrobial chemotherapy.2016;59(6):1247-60. [DOI:10.1093/jac/dkl460] [PMID]
12. Melendez PR, Johnson RH.Bacteremia and septic arthritis caused by Moraxella catarrhalis. Reviews of Infectious Diseases. 1991;13(3): 428-9. [DOI:10.1093/clinids/13.3.428] [PMID]
13. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-four informational supplement. M100-S21. Wayne Pa: CLSI; 2016.
14. Martins M, McCusker MP, Viveiros M, Couto I, Fanning S, Pagès JM, Amaral L. A simple method for assessment of MDR bacteria for over-expressed efflux pumps. The open microbiology journal. 2013; 7:72 [DOI:10.2174/1874285801307010072] [PMID] [PMCID]
15. Martins M, Santos B, Martins A, Viveiros M, Couto I, Cruz A. An instrument-free method for the demonstration of efflux pump activity of bacteria. In Vivo. 2006; 20(5): 657-664.
16. Ghaznavi Rad A, Zarei R, Jafari A, Palizwan M.R, Jourabchi A, Moeini L, Rafiei M. Prevalence of Moraxella catarrhalis and risk factors for it in patients with respiratory infections referred to Valiasr and Amirkabir hospitals in Arak.Yafte. 2005;7(4):117-122
17. Sillanpass S, Oikarinen S,Sipila M,kramna L, Rautianen M,Huhtala H et al.Moraxella catarrhalis Might Be More Common than Expected in Acute Otitis Media in Young Finnish Children. J Clin Microbiol.2016; 54(9): 2373-2379. [DOI:10.1128/JCM.01146-16] [PMID] [PMCID]
18. Miravitlles M, Espinosa C, FernandezLaso E, Martos JA, Maldonado JA,Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest.1999; 116(1):40-6 [DOI:10.1378/chest.116.1.40] [PMID]
19. Naderi H,Bakhshaei M,qzvini K,Zamanian A,Haghighi ZH. Prevalence of moraxlacataralysis carriers in the nasopharynx of healthy children under 6 years of age in kindergartens in Mashhad and determination of antibiotic resistance pattern in isolated moraxella catarrhalis.Iran J Otorhinolaryngol.2007;18(46):169-173
20. Bandet T, Whitehead S, Blondel-Hill E, Wagner K, Cheeptham N. Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents.Can J Infect Dis Med Microbiol.2014;25(3):155-158 [DOI:10.1155/2014/370964] [PMID] [PMCID]
21. Abdullah FE, Ahuja KR, Kumar H. Prevalence and emerging resistance of Moraxella catarrhalis in lower respiratory tract infections in Karachi. J Pak Med Assoc. 2013;63(11):1342-4
22. Ramana B V,Chaudhury. Antibiotic sensitivity pattern of Moraxella catarrhalis at a tertiary care hospital. IJPLS.2012;3(7):1805-6
23. Kafilzadeh F, Farsimadan F. Investigating multidrug efflux pumps in relation to the antibiotic resistance pattern in Escherichia coli strains from patients in Iran. Biomedical Research 2016; 27 (4): 1130-1135
24. Spaniol V, Wyder S, Aebi C. RNA-Seq-based analysis of the physio- logic cold shock-induced changes in Moraxella catarrhalis gene expression. PLoS One.2013;8(12):10.1371 [DOI:10.1371/annotation/a6e15b35-386c-4b0a-9de9-6fea091e9088]
25. Shriram V,Khare T,Bhagwat R,Shukla R, Kumar V. Inhibiting Bacterial Drug Efflux Pumps via Phyto-Therapeutics to Combat Threatening Antimicrobial Resistance. Front Microbiol.2018;9(2990) [DOI:10.3389/fmicb.2018.02990] [PMID] [PMCID]
26. Sonnet P, Izard D, Mullié C.Prevalence of effluxmediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine arginineßnaphthylamide. Int J Antimicrobial .2012 ; 39: 77- 80 [DOI:10.1016/j.ijantimicag.2011.08.005] [PMID]
27. Barrero MAO, Pietralonga P a. G, Schwarz DGG,Silva A, Paula SO, Moreira M a. S.Effect of the inhibitors phenylalanine arginyl ßnaphthylamide (PAßN) and 1-(1-naphthylmethyl)-piperazine (NMP) on expression of genes in multidrug efflux systems of Escherichia coli isolates from bovine mastitis.Res Vet Sci.2014;97(2):176-81. [DOI:10.1016/j.rvsc.2014.05.013] [PMID]
28. Moazzen Z, Eslami G, Hashemi A, Yousefi Nojookambari N. Efflux Pump Inhibitor Carbonyl Cyanide 3-Chlorophenylhydrazone (CCCP) Effect on the Minimum Inhibitory Concentration of Ciprofloxacin in Acinetobacter baumannii Strains. Arch Clin Infect Dis.2018;13(2): e59644 [DOI:10.5812/archcid.59644]
29. Gholami M, Hashemi A, Hakemi-Vala M, Goudarzi H, Hallajzadeh M. Efflux pump inhibitor phenylalanine-arginine Β-Naphthylamide effect on the minimum inhibitory concentration of imipenemin Acinetobacter baumannii strains isolated from hospitalized patients in Shahid Motahari Burn Hospital, Tehran, Iran. Jundishapur J Microbiol. 2015; 8(10): 1-7 [DOI:10.5812/jjm.19048] [PMID] [PMCID]
30. Dal T, Aksu B, Pages J.M and Over-Hasdemir U. Expression of the adeB gene and responsiveness to 1 (1-naphthylmethyl)-piperazine and phenylalanyl arginylb- naphthylamide in clinical isolates ofAcinetobacter baumannii. J Antimicrob Chemother.2013; 1-3. [DOI:10.1093/jac/dks511] [PMID]
31. Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 2010; 93-65:1589 [DOI:10.1093/jac/dkq218] [PMID]
32. Mavri A. Mozˇina S.S. Involvement of efflux mechanisms in biocide resistance of Campylobacter jejuni and Campylobacter coli. J Med Microbiol.2012; 61: 800-8. [DOI:10.1099/jmm.0.041467-0] [PMID]
33. Sharma A, Gupta VK, Pathania R. Efflux pump inhibitors for bacterial pathogens: From bench to bedside. Indian J Med Res.2019; 149(2):129-145 [DOI:10.4103/ijmr.IJMR_2079_17] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc